Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Acute Myeloid Leukemia and High-Risk Myelodsplastic Syndrome

NCT02641002 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02641002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02641002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Acute Myeloid Leukemia and High-Risk Myelodsplastic Syndrome
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Terminated
Start date
March 1, 2016
Completion date
July 18, 2018
Enrollment
28 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute, myelodysplastic syndromes